РАСПРОСТРАНЕННОСТЬ ГИПЕРГОМОЦИСТЕИНЕМИИ В ЗАВИСИМОСТИ ОТ СТАДИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК

ЦЕЛЬ ИССЛЕДОВАНИЯ. Исследование уровня гомоцистеина плазмы у больных на разных стадиях хронической болезни почек (ХБП). ПАЦИЕНТЫ И МЕТОДЫ. Методом высокоэффективной жидкостной хроматографии определен уровень обще го гомоцистеина (Hcy) плазмы у 219 больных с разными стадиями ХБП, из них 125 больных на додиализном этапе и 94 больных, получающих лечение хроническим бикарбонатным гемодиализом. РЕЗУЛЬТАТЫ. Распространенность гипергомоцистеинемии высока уже на начальных стадиях ХБП и увеличивается по мере снижения СКФ, достигая максимума в группе диализных больных. Выявлена обратная зависимость между величиной СКФ и уровнем Нсу плазмы в группе больных, не получающих диализного лечения. ЗАКЛЮЧЕНИЕ. Повышение уровня гомоцистеина плазмы отмечается, начиная с ранних стадий ХБП, и достигает максимально высоких значений и встречаемости у пациентов, получающих терапию гемодиализом.

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [ Suppl 3]: S112S119

2. Friedman AN, Bostom AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181 2189

3. McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA 1998; 279 (5): 392393

4. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274 (13): 10491057

5. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 17751781

6. Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland homocysteine study. Am J Clin Nutr 2001; 74(1): 130 – 136

7. Hoogeveen EK, Kostense PJ, Jakobs C et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5year followup of the hoorn dtudy. Circulation 2000; 101(13): 1506 – 1511

8. Jungers P, Chauveau P, Bandin O et al. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients. Miner Electrolyte Metab 1997; 23 : 170173

9. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 27432748;

10. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in endstage renal disease. Circulation 1998; 97:138 141;

11. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997;17: 25542558

12. Levey AS, Borsch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine a new prediction indication. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 471 482

13. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1266

14. Zhloba AA, Blashko EL. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800 (12): 275280

15. Francis ME, Eggers P W, Hostetter T H, Briggs J P. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004; 66 (1): 303312

16. Arnadottir M, Hultberg B, NilssonEhle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56 (1): 4146

17. Wollesen F, Brattstrom L, Refsum H et al. Plasma total homocysteine and cysteine in relation to GFR in diabetes mellitus. Kidney Int 1999; 55 (3): 10281035

18. Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 1020

19. Culleton BF, Bostom AG. Hyperhomocysteinemia in chronic renal disease. In: Loscalzo J, London GM (eds.) Cardiovascular disease in end stage renal failure. New York: Oxford university press; 2000: 211228

20. Rosenthal AF, Ginsberg MJ, Crawford JF. Homocysteine and heart disease in dialysis patients. Dial Transplant 1998; 27 (10): 627630

21. Bostom AG, Shemin D, Lapane KL et al. High dose B vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49 (1): 147152

22. van Guldener C, Janssen MJFM, Lambert J et al. No change in impaired endothelial function after longterm folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106112

23. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta analysis. Thromb Haemost 1998; 80: 8747

24. Ray JG. Metaanalysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 21012106

25. Shemin D, Lapane KL, Bausserman L et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999; 10: 10951099

26. Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 2004; 44(3): 43745

27. Смирнов АВ, Жлоба АА, Барабанова ВВ и др. Ги пергомоцистеинемия как фактор повреждения почек. Нефрология 2004; 8 [прил 2]: 284.

28. Kumagai H, Katoh S, Hirosawa K et al. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62: 12191228;

29. Li N, Chen Y, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002; 39: 443448;

30. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma in urine. Clin Chem 1985; 31: 624628

31. Foreman JW, Wald H, Blumberg G et al. Homocystine uptake in isolated rat renal cortical tubules. Metabolism 1982; 31: 613–619

32. Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217–246

33. Gaull GE, von Berg W, Raiha NCR, Sturman JA. Development of methyltransferase activities of human fetal tissues. Pediatr Res 1973; 7: 527–533

34. Bao L, Vlcek C, Paces V, Kraus JP. Identification and tissue distribution of human cystathionine Іsynthase mRNA isoforms. Arch Biochem Biophys 1998; 350: 95–103

35. Sturman JA, Rassin DK, Gaull GE. Distribution of transulphuration enzymes in various organs and species. Int J Biochem 1970; 1: 251253

36. van Guldener C, Donker AJM, Jakobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54 (1): 166169

37. Fowler B. The folate cycle and disease in humans. Kidney Int 2001; 59 [Suppl 78]: 221229

38. Massy Z A. Reversal of hyperhomocyst(e)inaemia in chronic renal failure—is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14: 28102812

39. van Guldener C, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56 (3): 10641071

40. Stam F, van Guldener C, ter Wee PM et al. Effect of folic acid on methionine and homocysteine metabolism in endstage renal disease. Kidney Int 2005; 67(1): 259264

41. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40(4): 230 235

42. van Guldener C, Janssen MJFM, de Meer K et al. Effect of folic acid and betaine on fasting and postmethionineloading plasma homocysteine and methionine levels in chronic hemodialysis patients. J Int Med 1999; 245: 175183

43. Fodinger M, Wagner OF, Horl WH, SunderPlassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001; 59 (S78): S238 242

44. Fodinger M, Buchmayer 1 H, Heinz G et al. Effect of MTHFR 1298AC and MTHFR677CT genotypes on total homocysteine, folate, and vitamin B12 plasma concentrations in kidney graft recipients. J Am Soc Nephrol 2000; 11(10): 1918 1925

45. SunderPlassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int 2003; 63 (s84): 141144

46. Feix A, FritschePolanz Rt, Kletzmayr J et al. Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis 2001; 38 (5): 956 – 964

47. Tsai MY, Garg U, Key NS et al. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 1996; 122: 6977

48. Gaustadnes M, Rudiger N, Rasmussen K et al. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost 2000; 83: 554558

49. de Franchis R, Fermo I, Mazzola G et al. Contribution of the cystathionine betasynthase gene (844ins68) polymorphism to the risk of earlyonset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 57682

50. Добронравов ВА, Ларионова ВИ, Смирнов АВ и др. Подходы к анализу роли молекулярногенетических и средовых факторов в развитии сердечнососудистой патологии у больных на диализе. Нефрология 2003; 7 [Прил. 1]: 2931